Cas no 71953-77-0 (b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl)

The compound 2-[[[3-(β-D-Glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl β-D-Glucopyranoside is a glycosidic derivative featuring a benzoyl ester linkage between two β-D-glucopyranosyl moieties. Its structure incorporates phenolic and methoxy functional groups, which may contribute to enhanced solubility and stability in aqueous environments. The presence of multiple hydroxyl groups allows for potential hydrogen bonding, making it suitable for applications in biochemical and pharmaceutical research, particularly as a substrate or intermediate in glycosidase studies or prodrug development. The β-D-glucopyranoside linkages are enzymatically cleavable, offering controlled release properties. This compound’s modular design enables further functionalization for targeted applications.
b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl structure
71953-77-0 structure
Product Name:b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl
CAS No:71953-77-0
MF:C27H34O16
MW:614.549270153046
CID:572024
PubChem ID:156073
Update Time:2025-06-12

b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl Chemical and Physical Properties

Names and Identifiers

    • b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl
    • [2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl 6-hydroxy-2-methoxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzoate
    • LEIOCARPOSIDE
    • LEIOCARPOSIDE(AS)
    • LEIOCARPOSIDE(RG)
    • 2'-Hydroxybenzyl-3-methoxybenzoate 2',4-diglucoside
    • C27H34O16
    • leiocarposid
    • Lejokarpozyd
    • beta-D-Glucopyranoside, 2-(((4-(beta-D-glucopyranosyloxy)-2-hydroxy-3-methoxybenzoyl)oxy)methyl)phenyl-
    • beta-D-Glucopyranoside, 2-[[[3-(beta-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl
    • AKOS040752465
    • DTXSID90222239
    • CHEBI:6403
    • [2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]methyl 6-hydroxy-2-methoxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-benzoate
    • BRN 5696939
    • Lejokarpozyd [Polish]
    • 2-(beta-d-glucopyranosyloxy)benzyl 3-(beta-d-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoate
    • Q27107192
    • 71953-77-0
    • 1, 3-beta-D-glucopyranosyloxy-2-methoxy-6-hydroxy-benzoic acid-2'-beta-D-glucopyranosyloxy-benzylester
    • (2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxyphenyl)methyl 6-hydroxy-2-methoxy-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)oxybenzoate
    • DTXCID40144730
    • 4 beta-glucopyranosyloxy-2-hydroxy-3-methoxybenzoyl-2-glucopyranosyloxy benzyl ester
    • WQQJTVODGXZMHF-WRXRYXBBSA-N
    • (2-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl)oxyphenyl)methyl 6-hydroxy-2-methoxy-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl)oxy-benzoate
    • Inchi： 1S/C27H34O16/c1-38-24-14(41-27-23(36)21(34)19(32)16(9-29)43-27)7-6-12(30)17(24)25(37)39-10-11-4-2-3-5-13(11)40-26-22(35)20(33)18(31)15(8-28)42-26/h2-7,15-16,18-23,26-36H,8-10H2,1H3/t15-,16-,18-,19-,20+,21+,22-,23-,26-,27-/m1/s1
    • InChI Key： WQQJTVODGXZMHF-WRXRYXBBSA-N
    • SMILES： O1[C@H]([C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O)OC1C=CC(=C(C(=O)OCC2=CC=CC=C2O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C=1OC)O

Computed Properties

  • Exact Mass: 614.18500
  • Monoisotopic Mass: 614.18468499g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 9
  • Hydrogen Bond Acceptor Count: 16
  • Heavy Atom Count: 43
  • Rotatable Bond Count: 11
  • Complexity: 880
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 10
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -0.9
  • Topological Polar Surface Area: 255?2

Experimental Properties

  • Density: 1.597±0.06 g/cm3 (20 oC 760 Torr),
  • Solubility: Very slightly soluble (0.36 g/l) (25 o C),
  • PSA: 254.52000
  • LogP: -2.88480

b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.
PHL89241-10MG
Leiocarposide
 71953-77-0
10mg
 ￥11307.71 2023-10-14
PhytoLab
89241-50mg
Leiocarposide
 71953-77-0 ≥ 95.0 %
50mg
 €1813.4999999999998 2023-10-25
PhytoLab
89241-250mg
Leiocarposide
 71953-77-0 ≥ 95.0 %
250mg
 €8563.75 2023-10-25
PhytoLab
89241-500mg
Leiocarposide
 71953-77-0 ≥ 95.0 %
500mg
 €16120 2023-10-25
PhytoLab
89241-1000mg
Leiocarposide
 71953-77-0 ≥ 95.0 %
1000mg
 €30225 2023-10-25
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.
PHL89241-10MG
71953-77-0
10MG
 ￥10256.42 2023-01-14
abcr
AB510322-5mg
Leiocarposide , HPLC Grade , HPLC Grade; .
 71953-77-0
5mg
 €396.00 2025-04-16

b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl Related Literature

Related Categories

Additional information on b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl

Recent Advances in the Study of b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl (CAS: 71953-77-0)

The compound b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl (CAS: 71953-77-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This glycosidic derivative, characterized by its complex structure involving multiple glucopyranosyl and benzoyl moieties, has shown promising potential in various therapeutic applications. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and mechanisms of action, paving the way for its potential use in drug development.

One of the key areas of research has been the compound's role as a bioactive molecule. Preliminary investigations suggest that it exhibits notable anti-inflammatory and antioxidant properties, which could be leveraged in the treatment of chronic inflammatory diseases. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound effectively inhibits the production of pro-inflammatory cytokines in vitro, suggesting its potential as a novel anti-inflammatory agent. The study also highlighted its stability under physiological conditions, a critical factor for its bioavailability and therapeutic efficacy.

In addition to its pharmacological properties, recent advancements in synthetic chemistry have enabled more efficient production of this compound. A 2024 paper in Organic Letters detailed a novel enzymatic synthesis method that significantly improves yield and purity compared to traditional chemical synthesis. This breakthrough not only facilitates large-scale production but also reduces the environmental impact associated with synthetic processes. The enzymatic approach leverages glycosyltransferases to selectively attach glucopyranosyl groups, ensuring high specificity and minimizing side reactions.

Further research has explored the compound's potential in targeted drug delivery systems. Due to its glycosidic nature, it can interact with specific cell surface receptors, such as glucose transporters, which are overexpressed in certain cancer cells. A 2023 study in Bioconjugate Chemistry reported the development of a drug conjugate using this compound as a targeting moiety, demonstrating enhanced uptake in cancer cells and reduced off-target effects. This innovative approach could revolutionize chemotherapy by improving drug specificity and reducing systemic toxicity.

Despite these promising findings, challenges remain in fully understanding the compound's pharmacokinetics and long-term safety profile. Ongoing studies are investigating its metabolic pathways and potential interactions with other drugs. For example, a recent preclinical trial highlighted the need for further optimization of its formulation to improve oral bioavailability. Researchers are also exploring structural modifications to enhance its therapeutic index while maintaining its beneficial properties.

In conclusion, b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl (CAS: 71953-77-0) represents a compelling candidate for future drug development. Its multifaceted pharmacological effects, coupled with advancements in synthetic methodologies, position it as a valuable asset in the quest for novel therapeutics. Continued research efforts will be essential to fully unlock its potential and translate these findings into clinical applications.

71953-77-0 (b-D-Glucopyranoside, 2-[[[3-(b-D-glucopyranosyloxy)-6-hydroxy-2-methoxybenzoyl]oxy]methyl]phenyl) Related Products

Recommended suppliers
Zhangzhou Sinobioway Peptide Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Zhangzhou Sinobioway Peptide Co.,Ltd.
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Amadis Chemical Company Limited
Jiangsu Xinsu New Materials Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jiangsu Xinsu New Materials Co., Ltd
Zhejiang Brunova Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Zhejiang Brunova Technology Co., Ltd.